Disulfide high mobility group box-1 causes bladder pain through bladder Toll-like receptor 4 Journal Article

Local Library Link: Find It @ Loyola

Authors: Ma, F.; Kouzoukas, D. E.; Meyer-Siegler, K. L.; Westlund, K. N.; Hunt, D. E.; Vera, P. L.
Article Title: Disulfide high mobility group box-1 causes bladder pain through bladder Toll-like receptor 4
Abstract: BACKGROUND: Bladder pain is a prominent symptom in several urological conditions (e.g. infection, painful bladder syndrome/interstitial cystitis, cancer). Understanding the mechanism of bladder pain is important, particularly when the pain is not accompanied by bladder pathology. Stimulation of protease activated receptor 4 (PAR4) in the urothelium results in bladder pain through release of urothelial high mobility group box-1 (HMGB1). HGMB1 has two functionally active redox states (disulfide and all-thiol) and it is not known which form elicits bladder pain. Therefore, we investigated whether intravesical administration of specific HMGB1 redox forms caused abdominal mechanical hypersensitivity, micturition changes, and bladder inflammation in female C57BL/6 mice 24 hours post-administration. Moreover, we determined which of the specific HMGB1 receptors, Toll-like receptor 4 (TLR4) or receptor for advanced glycation end products (RAGE), mediate HMGB1-induced changes. RESULTS: Disulfide HMGB1 elicited abdominal mechanical hypersensitivity 24 hours after intravesical (5, 10, 20 mug/150 mul) instillation. In contrast, all-thiol HMGB1 did not produce abdominal mechanical hypersensitivity in any of the doses tested (1, 2, 5, 10, 20 mug/150 mul). Both HMGB1 redox forms caused micturition changes only at the highest dose tested (20 mug/150 mul) while eliciting mild bladder edema and reactive changes at all doses. We subsequently tested whether the effects of intravesical disulfide HMGB1 (10 mug/150 mul; a dose that did not produce inflammation) were prevented by systemic (i.p.) or local (intravesical) administration of either a TLR4 antagonist (TAK-242) or a RAGE antagonist (FPS-ZM1). Systemic administration of either TAK-242 (3 mg/kg) or FPS-ZM1 (10 mg/kg) prevented HMGB1 induced abdominal mechanical hypersensitivity while only intravesical TLR4 antagonist pretreatment (1.5 mg/ml; not RAGE) had this effect. CONCLUSIONS: The disulfide form of HMGB1 mediates bladder pain directly (not secondary to inflammation or injury) through activation of TLR4 receptors in the bladder. Thus, TLR4 receptors are a specific local target for bladder pain.
Journal Title: BMC physiology
Volume: 17
Issue: 1
ISSN: 1472-6793; 1472-6793
Publisher: Unknown  
Journal Place: England
Date Published: 2017
Start Page: 6
End Page: 017-0032-9
Language: eng
DOI/URL:

10.1186/s12899-017-0032-9
Notes: LR: 20170526; JID: 101088687; OTO: NOTNLM; 2016/12/09 [received]; 2017/05/18 [accepted]; epublish